<DOC>
	<DOC>NCT03010579</DOC>
	<brief_summary>This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.</brief_summary>
	<brief_title>Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Lymphoma patients with anemia on day +15 post-transplant will be randomized to erythropoietin group or control group. Potential benefit of erythropoietin will be evaluatedon day +60 post-transplant.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>confirmed lymphoma first autologous hematopoietic stem cell transplantation hemoglobin level less than 100 g/L on day +15 posttransplant written informed consent given by patient or his/her guardian if of minor age. HIV positive Known allergy to recombinant human erythropoietin Uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>